10/30/2026
The FDA wants to talk about abortion pills after the midterms. We need to talk about them NOW.
The Trump administration plans to delay releasing its review of mifepristone, a medication widely used in abortion care, until March 2027—after the 2026 midterm elections.
Why does the timing matter? Because the findings could be used to justify new restrictions on medication abortion, potentially affecting access even in states where abortion remains legal.
The FDA’s review also comes as the administration faces legal challenges over telehealth access to abortion pills. These decisions could have far-reaching consequences for reproductive healthcare nationwide.
This is about more than one medication. It’s about who gets to make decisions about our bodies, our healthcare and our futures.
We cannot afford to look away until after the votes are counted. Reproductive rights belong in the conversation before we head to the ballot box.
📢 Stay informed. Speak up. Vote for candidates who will protect reproductive freedom and access to comprehensive healthcare.
Read the full article from Ms. Magazine and join us in keeping reproductive rights in focus.